Response to Sorafenib in a Patient with Metastatic Xp11 Translocation Renal Cell Carcinoma

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.11, 2010-11, pp. : 799-804

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma - a flawed analysis and a problematic response

By Hoaglin David C

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 12, 2013-08 ,pp. : 1705-1706

Informa Healthcare

Access to resources Recommend Favorite

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis?

By Hoaglin David C Cislo Paul R

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 1077-1078

Informa Healthcare

Access to resources Recommend Favorite

Onset of Male Gynaecomastia in a Patient Treated with Sunitinib for Metastatic Renal Cell Carcinoma

By Ballardini Pierluigi

Clinical Drug Investigation, Vol. 29, Iss. 7, 2009-06 ,pp. : 487-490

Adis International

Access to resources Recommend Favorite

Complete Clinical Response to Cetuximab in a Patient with Metastatic Cutaneous Squamous Cell Carcinoma

By MILLER KRISTEN SHERMAN WILLIAM RATNER DÉSIRÉE

Dermatologic Surgery, Vol. 36, Iss. 12, 2010-12 ,pp. : 2069-2074

Elsevier

Access to resources Recommend Favorite

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

By Di Lorenzo Giuseppe Casciano Roman Malangone Elisabetta Buonerba Carlo Sherman Steven Willet Jacob Wang Xufang Liu Zhimei De Placido Sabino

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1491-1497

Informa Healthcare

Access to resources Recommend Favorite